Inactive Instrument

Press Releases Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	Jun. 18	AQ
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even	Jun. 18	AQ
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix	Jun. 10	AQ
Santhera Publishes Agenda for its Annual General Meeting	May. 28	AQ
Santhera Publishes Annual Report 2023	May. 28	AQ
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	Apr. 25	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	Mar. 27	AQ
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	Mar. 14	AQ
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	Feb. 14	AQ
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	Jan. 15	AQ
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom	Jan. 12	AQ
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	Dec. 18	AQ
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage	Dec. 07	AQ
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals	23-10-27	AQ
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	23-10-27	AQ
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	23-10-13	AQ
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update	23-09-07	AQ
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group	23-07-31	AQ
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone	23-07-19	AQ
Santhera Publishes Timeline of the Reverse Share Split	23-06-29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Santhera Pharmaceuticals Holding AG Xetra

Equities

S3F

CH0027148649

Press Releases

Filters